Optimized Mucoadhesive Coated Niosomes as a Sustained Oral Delivery System of Famotidine

AAPS PharmSciTech
Al-Zahraa M Khalifa, Bazigha K Abdul Rasool

Abstract

The objective of this study is to develop an oral formulation of famotidine niosomes coated with a mucoadhesive polymer, chitosan. Famotidine (FMT) has low oral bioavailability of 40-45% and short half-life between 2.5 to 4 h. Famotidine is classified as class IV in BCS because of its low aqueous solubility (0.1% w/v) and low permeability. Thus, FMT was loaded to the bioadhesive coated niosomes to improve its solubility, enhance its oral bioavailability, and sustain FMT release pattern. Different formulations were prepared by thin-film hydration method and characterized in terms of entrapment efficiency, morphological features, vesicle size, and zeta potential. In vitro release and ex vivo permeability of famotidine from the formulations were evaluated. The optimized formula was coated with chitosan and its mucoadhesion and stability in bile salt was tested. The optimized formula showed a high entrapment efficiency of 74%, as well sustained the in vitro release of FMT in the simulated gastric medium and enhanced its permeation through an excised goat's intestinal membrane by 1.4 fold in comparison to FMT control suspension. The mucoadhesive coated formula exhibited a significantly higher (p < 0.05) mucoadhesive efficiency and m...Continue Reading

References

Dec 5, 1980·Biochimica Et Biophysica Acta·R N Rowland, J F Woodley
Jul 1, 1995·Journal of Microencapsulation·C P Jain, S P Vyas
Feb 24, 2001·Journal of Microencapsulation·J Filipović-GrcićI Jalsenjak
Sep 3, 2002·International Journal of Pharmaceutics·Yongmei HaoKe'an Li
Nov 13, 2003·Drug Delivery·Jaleh VarshosazAbdolhossein Rouholamini Najafabadi
Jan 25, 2005·International Journal of Pharmaceutics·Deepika Aggarwal, Indu P Kaur
Jun 26, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tao YangDae-Duk Kim
Apr 9, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Rania H Fahmy, Mohammed A Kassem
Jun 11, 2008·Biomacromolecules·Ioannis A SogiasVitaliy V Khutoryanskiy
Sep 26, 2009·Journal of Pharmaceutical Sciences·Zerrin Sezgin Bayindir, Nilufer Yuksel
Jul 17, 2010·AAPS PharmSciTech·Kandasamy Ruckmani, Veintramuthu Sankar
Jun 7, 2011·Colloids and Surfaces. B, Biointerfaces·Surinder K MehtaGurpreet Kaur
Jul 13, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Shoshy MizrahyDan Peer
Nov 1, 2011·Colloids and Surfaces. B, Biointerfaces·Harshavardhan PawarJoshua S Boateng
Sep 6, 2012·Advances in Colloid and Interface Science·N B MahaleS R Chaudhari
May 30, 2014·International Journal of Nanomedicine·Il-Woo Jung, Hyo-Kyung Han
Jan 1, 2014·International Scholarly Research Notices·Sajal Kumar JhaD Harinarayana

❮ Previous
Next ❯

Citations

Aug 27, 2019·Drug Development and Industrial Pharmacy·Sadaf Jamal GilaniMohamad Taleuzzaman
Dec 9, 2020·Drug Development and Industrial Pharmacy·Mariana Domingues BianchinIrene Clemes Külkamp-Guerreiro
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Syed Sarim ImamBjad K Almutairy
Dec 28, 2021·Journal of Liposome Research·Sahar SalehiSajad Sahab-Negah

❮ Previous
Next ❯

Software Mentioned

SPSS®
Excel

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.